Guidelines

Latest Guidelines

 

European Guidelines for Treatment of HIV-Infected Adults in Europe

The October 2016 (version 8.1) guidelines provide recommendations on the assessment of patients with HIV infection at initial and follow-up visits, management of ART, prevention and management of comorbidities and opportunistic infections including HBV and HCV coinfection.
Download .pdf document
 

Updated guidelines for antiretroviral postexposure prophylaxis after sexual, injection drug use, or other nonoccupational exposure to HIV—United States, 2016

US recommendations on antiretroviral nonoccupational postexposure prophylaxis, including additional aspects of case management for individuals who experience isolated exposure to blood, genital secretions, or other body fluids that may contain HIV.
 

Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents

The recommendations in these guidelines are intended to provide the most current information to treatment providers on the use of antiretroviral agents to treat HIV infection in adults and adolescents in the United States. Topics addressed include baseline evaluation; laboratory testing; the goals of antiretroviral therapy; when to initiate therapy; which agents to use; which agents should not be used; management of treatment-experienced patients (including switch strategies for patients with virologic suppression and management approaches for patients with virologic failure or suboptimal immune response); considerations for the use of antiretroviral agents in special populations (acute/recent HIV infection, adolescents/young adults, illicit drug users, women, older patients, and patients infected with HIV-2); considerations for the use of antiretroviral agents in patients with hepatitis B virus, hepatitis C virus, or tuberculosis coinfection; limitations to the efficacy and safety of therapy; drug–drug interactions; and prevention of secondary HIV transmission.
Download .pdf document
 

Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents

The recommendations in this guideline are intended to provide critical knowledge to treatment providers on optimal strategies for diagnosing, preventing, and treating opportunistic infections in HIV-infected patients. The diseases/infections addressed in this guideline include: Pneumocystis pneumonia, Toxoplasma gondii encephalitis, cryptosporidiosis, Mycobacterium tuberculosis, disseminated Mycobacterium avium complex, bacterial respiratory disease, bacterial enteric infections, Bartonellosis, syphilis, mucocutaneous candidiasis, endemic mycoses plus aspergillosis, cytomegalovirus, noncytomegalovirus herpes, human papillomavirus, hepatitis B virus, hepatitis C virus, progressive multifocal leukoencephalopathy/JC virus, malaria, Penicilliosis marneffei, leishmaniasis, Chagas disease, and isosporiasis.
Download .pdf document
 

British HIV Association Guidelines for the Treatment of HIV-1-Positive Adults With Antiretroviral Therapy

In September of 2015, the British HIV Association updated their 2013 guidelines on the treatment of HIV-1 positive adults with antiretroviral therapy. These guidelines provide recommendations on when to start therapy, therapy strategies, support for patients during therapy, managing virological failure, and addresses therapy considerations in specific populations.
Download .pdf document
 
 
 

Sexually Transmitted Diseases Treatment Guidelines

2015 CDC treatment guidelines for sexually transmitted infections.
Download .pdf document
 

Committee Opinion No. 635: Prenatal and Perinatal Human Immunodeficiency Virus Testing: Expanded Recommendations

The Committee on Obstetric Practice and HIV Expert Work Group from the American College of Obstetricians and Gynecologists provides recommendations on when and in whom HIV testing should be performed during pregnancy.
Download .pdf document
 

Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection

The recommendations in these guidelines address combination antiretroviral therapy use in HIV-infected infants, children, and adolescents (through the end of puberty), including information on managing adverse events associated with treatment. The February 2014 updates to the previous November 2012 version include new guidance on the diagnosis of HIV infection in exposed infants, clinical and laboratory monitoring of HIV, when to start antiretroviral therapy, recommended first-line regimens, special considerations for antiretroviral treatment of infants younger than 15 days of age and premature infants, switch strategies to simplify treatment or reduce toxicity, identification and management of treatment failure, the impact of structured antiretroviral therapy interruptions, the role of therapeutic drug monitoring, and new pediatric information on antiretroviral agents.
Download .pdf document